According to ZMC, the new subsidiary has a special status in being a ‘named subsidiary’ of the parent company. This is said to assure brand holders of consistent supply, and to assure them that the transparency of where source materials come from and how they are made that is increasingly required under more stringent GMP enforcement will be delivered. Certificates of Analysis and other documents are increasingly being required to be from the original manufacturer and not altered by a distributor as has been previously accepted policy.
ZMC said the new subsidiary will also provide the parent company a way to participate in the market through trade show sponsorships, trade publication advertising and support to trade industry associations. The company said these activities ultimately promote the exchange of ideas amongst industry members and encourage cooperation within and support for the nutritional industry.
Zhejiang Medicine Company (ZMC) an active ingredient manufacturer of high quality pharmaceutical and nutraceutical ingredients improving the lives of the world's consumers since 1954. ZMC is staffed with over 6,000 employees globally and is an important production base of pharmaceutical drugs, Biotin, Vitamin A, Astaxanthin, Natural and Synthetic Vitamin E, Patented Lutein, Phytosterol, Natural and Synthetic Beta-Carotene, Zeaxanthin, Patented Lycopene, and Coenzyme Q10.